200 Penobscot Drive
Redwood City, CA 94063
United States
650 421 8100
https://www.codexis.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 174
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Stephen George Dilly MBBS, Ph.D. | President, CEO & Chairman | 1.88M | N/A | 1960 |
Mr. Sriram Ryali M.B.A. | Chief Financial Officer | 770.45k | N/A | 1981 |
Mr. Kevin Norrett M.B.A., M.S. | Chief Operating Officer | 739.56k | N/A | 1973 |
Carrie McKim | Director of Investor Relations | N/A | N/A | N/A |
Ms. Margaret Nell Fitzgerald J.D. | Chief Legal & Compliance Officer, General Counsel and Secretary | 300.03k | N/A | 1971 |
Ms. Karen Frechou-Armijo | Senior VP & Head of Human Resources | N/A | N/A | N/A |
Dr. Stefan Lutz Ph.D. | Senior Vice President of Research | N/A | N/A | N/A |
Mr. Robert Sato M.B.A., Ph.D. | Senior Vice President of Pharmaceutical Development, Quality & Regulatory | N/A | N/A | N/A |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Codexis, Inc.’s ISS Governance QualityScore as of September 1, 2024 is 6. The pillar scores are Audit: 3; Board: 3; Shareholder Rights: 8; Compensation: 8.